Cite
MLA Citation
G Geert R D'Haens et al.. “OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis.” Journal of Crohn's and colitis, vol. 13, n.d., pp. S026–S027. http://access.bl.uk/ark:/81055/vdc_100094047233.0x000007